The ATP Sensitive Inward Rectifier Potassium Channel 8 pipeline drugs market research report outlays comprehensive information on the ATP Sensitive Inward Rectifier Potassium Channel 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the ATP Sensitive Inward Rectifier Potassium Channel 8 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Dermatology, Cardiovascular, and Metabolic Disorders which include the indications Androgenic Alopecia, Acute Coronary Syndrome, Low Cardiac Output Syndrome, and Obesity. It also reviews key players involved in ATP Sensitive Inward Rectifier Potassium Channel 8 targeted therapeutics development with respective active and dormant or discontinued products.
The ATP Sensitive Inward Rectifier Potassium Channel 8 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, and Preclinical stages are 1, 2, and 2 respectively.
ATP Sensitive Inward Rectifier Potassium Channel 8 overview
ATP-Sensitive Inward Rectifier Potassium Channel 8 (KCNJ8) is a member of the inward rectifier potassium channel family. This channel is sensitive to intracellular ATP levels, and its activity is crucial for maintaining cellular homeostasis, particularly in response to changes in metabolic conditions. KCNJ8 is commonly found in cardiac tissue, where it contributes to the regulation of the resting membrane potential and helps shape the action potential. It plays a significant role in controlling the excitability of cardiac cells and modulating the duration of the cardiac action potential. Mutations or dysregulation of KCNJ8 have been implicated in certain cardiac arrhythmias and other cardiovascular disorders.
For a complete picture of ATP Sensitive Inward Rectifier Potassium Channel 8’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
